Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
Clinical outcomes for patients receiving 2L therapy post-osimertinib progression remain poor, highlighting an unmet need, particularly for those with brain and liver metastases.
Authors
- Yan Xiong (ORCID: https://orcid.org/0000-0003-1212-5516)
- Danalyn Byng (ORCID: https://orcid.org/0000-0002-8754-0530)
- Shannon Hunter (ORCID: https://orcid.org/0000-0001-9435-7737)
- Pauline Macouillard (ORCID: https://orcid.org/0000-0003-0110-2415)
- X. Quantin
- Alessandria Struebing (ORCID: https://orcid.org/0009-0007-1894-3372)
- Jie Meng (ORCID: https://orcid.org/0000-0002-6439-7292)
- Maurice Pérol
- Olga Tymejczyk
- C. Audigier-Valette
- Christos Chouaid
- Friso Coerts
- Lise Bosquet
- Nicolas Girard
- Sarah Park
- M. Inaam Haq
Institutions
- Daiichi Sankyo (Germany) (DE)
- Centre Léon Bérard (FR)
- Daiichi Sankyo (India) (IN)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Hôpital d'Instruction des Armées Sainte-Anne (FR)
- UniCancer Group (FR)
- Centre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer (FR)
- Groupe Hospitalier de la Région de Mulhouse et Sud Alsace (FR)
- Hôpital Intercommunal de Créteil (FR)
- Physique des Cellules et Cancers (FR)
- Daiichi Sankyo (United States) (US)
- Institut Curie (FR)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1007/s12325-025-03465-4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Université de Versailles Saint-Quentin-en-Yvelines
- Daiichi Sankyo Europe